fact sheet

GILEAD FUND
Summary sheet: 31 March 2015, page 1 of 2
Class A: E T A G X | Class C: E T C G X | Class I: E T I L X | Class N: E T G L X
The Eventide Gilead Fund is a
diversified mutual fund that seeks
to provide long-term capital
appreciation. The fund invests in
primarily equity securities of
companies that we believe
demonstrate values and business
practices that are ethical,
sustainable, and provide an
TOP HOLDINGS*
Macquarie Infrastructure Company (2.84%):
Aircraft services, liquid storage and marine terminals
bluebird bio (2.80%): New drugs for patients with
severe genetic and orphan diseases
Lowe’s Companies, Inc (2.69%): 1,800 home
improvement stores in the U.S., Canada and Mexico
Red Hat (2.38%): Distributing and supporting
open-source operating systems and middleware
Lear Corp (2.32%): Building seats and electrical
systems for cars
Trinity Industries, Inc (2.29%): Products and services
for the energy, transportation and chemical sectors
WABCO (2.22%): Control, braking, suspension and
other parts for cars and trucks
Palo Alto Networks (2.12%): Cybersecurity solutions
for enterprise and government clients
Magna International (2.09%): Developing and
building automotive systems
SunEdison Inc (2.03%): Solar power systems for
homes and businesses
Jul 2008–Mar 2015†
Growth of $10,000
08
Jan 10
Jan 09
Jan 11
Jan 12
Jan 13
Jan 14
Jan 15
30,328
attractive investment opportunity.
25,000
The fund also invests in securities
20,931
18,979
that have significant near-term
15,000
appreciation potential.
10,000
5,000
Eventide Gilead Fund‡
S&P 500 Total Return Index
Russell Midcap Growth Index
% as of 31 Mar 2015†
Fund Returns
0
3 Month**
Year to Date**
10
0.95
0.95
20
5.19
5.38
5.19
5.38
1 Year**
12.73
16.30
15.56
3 Year
(Annualized)
16.11
5 Year
(Annualized)
Inception
(Annualized)††
Eventide Gilead Fund‡
14.47
9.85
11.49
Russell Midcap Growth Index
24.85
17.41
20.42
16.43
17.95
S&P 500 Total Return Index
Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when
redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly
invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information
and a current Eventide Gilead Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).
* Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.
† These charts compare the Eventide Gilead Fund to index fund performance over the previous periods shown, and since inception. Since Inception returns pertain to Class N and are annualized and assume the inception date of 8 July 2008.
Performance will differ for other fund classes, based upon fees and commissions. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product available for
purchase. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth.
‡ Returns pertain to Class N.
** Aggregate total return, not annualized.
†† Annualized since inception returns assume an inception date of 8 July 2008.
GILEAD FUND
Summary sheet: 31 March 2015, page 2 of 2
Class A: E T A G X | Class C: E T C G X | Class I: E T I L X | Class N: E T G L X
OVERVIEW
Fund
Nasdaq
Sales Charge*
12b-1 Fees
Total Expenses
Inception Date
Class A
Class C
Class I
Class N
ETAGX
ETCGX
ETILX
ETGLX
Front-end: 5.75%
None
None
None
0.25%
1.00%
0.00%
0.20%
1.50%
2.25%
1.25%
1.45%
10/28/2009
10/28/2009
2/2/2010
7/8/2008
Minimum Investment: $1,000 or $100 with AIP (Class A, C, N), $100,000 (Class I)
Net assets: $1.42 billion
Portfolio Composition†
0
10
% of portfolio
20
30
Large Cap
40
24.88
Mid Cap
Small Cap
50
49.95
6.95
Other
18.21
Value
Blend
Growth
Cash/Other
Sector Allocation‡
% of portfolio
Technology
Health Care
Industrials
Consumer Discret.
Energy
Financials
Utilities
Materials
Consumer Staples
Cash/Other
Equity market capitalization: $13.16B average, $6.59B median
David Barksdale has a background in software
development, engineering and management and is
primarily responsible for quantitative research, risk
analysis and asset allocation. He holds a bachelor’s
degree from Caltech in Engineering & Applied
Science. By developing and applying novel
analytical tools and strategies, Mr. Barksdale works
to optimize portfolio returns on a risk-adjusted basis.
Market Risk**
3 Year
(Annualized)
5 Year
(Annualized)
Inception
(Annualized)††
Std. Dev.
Beta
Alpha
R-Squared
13.05%
0.94
8.96%
48.02%
18.16%
1.23
2.66%
77.08%
19.85%
1.00
7.95%
70.25%
21.50
17.96
15.96
12.45
4.15
3.89
2.74
2.21
0.92
18.21
MANAGERS
Dr. Finny Kuruvilla has a unique background in
healthcare, statistics, and investing. He holds an MD
from Harvard Medical School, a PhD in Chemistry
and Chemical Biology from Harvard University, a
master’s degree in Electrical Engineering and
Computer Science from MIT, and a bachelor’s degree
from Caltech in Chemistry. He completed his
residency and fellowship at the Brigham & Women's
Hospital and Children's Hospital Boston where he
cared for adult and pediatric patients suffering from
a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research
fellow at MIT where he designed and implemented
statistical algorithms involving logistic regression
and pseudo-Bayesian expectation maximization. As
an avid proponent of values-based investing, Dr.
Kuruvilla has developed standards for selecting
ethical companies at the outset of the stock selection
process.
* Other expenses that apply to a continued investment in the fund are described in the Fund's prospectus.
† Companies valued at greater than $10 billion are Large Cap; those at less than $1 billion are Small Cap. Portfolio Composition is subject to change at any time. Past performance does not assure future results.
‡ The Fund may not invest 25% or more of its total assets in a particular industry or group of industries. A sector is normally composed of many industry groups. Sector Allocation is subject to change at any time. Past performance does not assure
future results.
** Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc. From inception to March 31, 2015, Fund performance statistics were calculated using daily statistical information. As of March 31, 2015, performance is
derived from Zephyr StyleADVISOR, which reflects monthly statistical data. The methodology has been changed to meet industry norms to allow for ease of comparison with other providers, and does not affect the consistency of the data itself.
Summary sheets prior to March 31, 2015 used daily data.
Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over
the specified period. Beta is a measure of systematic risk, or the sensitivity of ETGLX to movements in the the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETGLX and Index divided by the variance of the Index. Alpha is
the mean of the excess return of ETGLX over beta times the Index. The R-Squared (R2) of ETGLX versus the Index is a measure of how closely related the variance of ETGLX returns and the variance of the Index returns are. StyleADVISOR calculates
R2 by squaring the correlation of monthly returns between ETGLX and the Index over the specified period.
†† Annualized since inception market risk details assume inception date of 1 August 2008 and not Class N's actual inception date of 8 July 2008, as only full month data is included in the market risk calculations.
Mutual Funds involve risk including the possible loss of principal.
Past performance does not guarantee future results. The fund can invest in smaller-sized companies which may experience higher failure rates than larger companies normally have a lower trading volume than
larger companies. The Fund’s ethical values screening criteria could cause it to under perform similar funds that do not have such screening criteria. The fund can have risk associated with the biotechnology and
pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The fund can have risk related to
option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal
standards.
Investors should consider the Fund's objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund
can be found in the fund's prospectus, which can be obtained at www.eventidefunds.com or by calling 877-771-EVEN (3836). Please read the prospectus carefully before investing. The Fund is
distributed by Northern Lights Distributors, Member FINRA, which is not affiliated with Eventide Asset Management, LLC.
Eventide Asset Management, LLC | 60 State Street, Ste. 700 | Boston, MA 02109 | 877-771-EVEN (3836) | W W W . E V E N T I D E F U N D S . C O M
4271-NLD-4/22/2015